Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
BQ.1.1.64NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBC.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.221.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
DP.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BL.1.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BN.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.177.62NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.82NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.20NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.3.22NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.38.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.79.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.47NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BF.7.18NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XAY.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.55NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BY.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EA.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XJNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BR.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBF.8NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.1.29NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CM.5.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CM.8.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.99NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBF.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.343NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.4.17 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.25.1.2 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.409NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.83NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.310NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.362.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.162NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Y.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.86NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.154NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.4.8NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
A.2.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.41NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.137NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.446NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.76 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.398NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.163NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
P.3 (Theta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.38.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XAVNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BE.1.4.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBC.1.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used